Buspirona [INN-Spanish] en es it fr

Buspirona [INN-Spanish] Brand names, Buspirona [INN-Spanish] Analogs

Buspirona [INN-Spanish] Brand Names Mixture

  • No information avaliable

Buspirona [INN-Spanish] Chemical_Formula


Buspirona [INN-Spanish] RX_link


Buspirona [INN-Spanish] fda sheet

Buspirona_[INN-Spanish] FDA

Buspirona [INN-Spanish] msds (material safety sheet)

Buspirona_[INN-Spanish] MSDS

Buspirona [INN-Spanish] Synthesis Reference

U.S. Pat. 3,717,634 (1973)

Buspirona [INN-Spanish] Molecular Weight

385.503 g/mol

Buspirona [INN-Spanish] Melting Point


Buspirona [INN-Spanish] H2O Solubility

21.4 mg/L

Buspirona [INN-Spanish] State


Buspirona [INN-Spanish] LogP


Buspirona [INN-Spanish] Dosage Forms

Tablet (5 mg, 10 mg)

Buspirona [INN-Spanish] Indication

For the management of anxiety disorders or the short-term relief of the symptoms of anxiety, and also as an augmention of SSRI-treatment against depression.

Buspirona [INN-Spanish] Pharmacology

Buspirone is used in the treatment of generalized anxiety where it has advantages over other antianxiety drugs because it does not cause sedation (drowsiness) and does not cause tolerance or physical dependence. Buspirone differs from typical benzodiazepine anxiolytics in that it does not exert anticonvulsant or muscle relaxant effects. It also lacks the prominent sedative effect that is associated with more typical anxiolytics. in vitro preclinical studies have shown that buspirone has a high affinity for serotonin (5-HT1A) receptors. Buspirone has no significant affinity for benzodiazepine receptors and does not affect GABA binding in vitro or in vivo when tested in preclinical models. Buspirone has moderate affinity for brain D2-dopamine receptors. Some studies do suggest that buspirone may have indirect effects on other neurotransmitter systems.

Buspirona [INN-Spanish] Absorption

Rapidly absorbed in man. Bioavailability is low and variable (approximately 5%) due to extensive first pass metabolism.

Buspirona [INN-Spanish] side effects and Toxicity

Oral, rat LD50 = 136 mg/kg. Symptoms of overdose include dizziness, drowsiness, nausea or vomiting, severe stomach upset, and unusually small pupils.

Buspirona [INN-Spanish] Patient Information

Buspirone is used for the treatment of nervousness and anxiety. Optimum results are usually seen after three to four weeks of treatment. This medication may be taken with or without food. Inform your physican if you are pregnant or nursing. Buspirone may cause dizziness and drowsiness; use caution while driving or operating hazardous machinery. Do not take any other sedating drugs or drink alcohol while taking this medication. Do not take this medication with a monoamine oxidase inhibitor. Notify physician if you develop muscle spasms, uncontrolled twitching in the face and body, or uncontrolled tongue movements.

Buspirona [INN-Spanish] Organisms Affected

Humans and other mammals